ADC
Site-specific conjugation of IgG with MMAE or PNU.
GlyCLICK is a site-specific conjugation technology for IgG using Fc glycan remodeling and click-chemistry. The technology generates stable and homogenous antibody conjugates for IgG from several species and subclasses. Fc-glycan remodeling by complete deglycosylation of the antibody allows for site-specific conjugation using robust click-chemistry, resulting in a degree of label (DOL) or drug-antibody ratio (DAR) of 2.
GlyCLICK ADC is available for site-specific labeling of 2 mg IgG with MMAE (Monomethyl auristatin E) or PNU (PNU anthracycline payload), and is suitable for the development of antibody-drug conjugates (ADCs).
MMAE is a potent cytotoxin that inhibits microtubule assembly and tubulin-dependent GTP hydrolysis, causing cell cycle arrest and apoptosis.
PNU is an anthracycline based DNA-alkylating toxin causing apoptosis with significantly higher potency that tubulin-targeting payloads.
- Site-specific payload-conjugation to IgG with a consistent drug-antibody ratio (DAR) of 2
- Unique linker payloads with a two-step enzymatic release mechanism
- Generates a site-specific ADC without antibody engineering
- Preserved immunoreactivity with greater control of cytotoxicity
Available Products
For information on how to order, visit Place an Order or contact us directly at order@genovis.com.
ADC Development
Unit Definition
GlyCLICK ADC contains sufficient material for labeling of 2 mg IgG. For larger amounts or evaluation of the technology, please contact us.
Content and Storage
Components in GlyCLICK ADC:
- GlycINATOR Immobilized
- UDP-GalNAz
- GalT(Y298L)
- sDIBO (MMAE or PNU)
- All buffers needed
- Concentration and desalting columns
Content should be stored at different temperatures upon arrival.
Support